Company Name	Pharmaxis Ltd
Registered Office	20 Rodborough Road Frenchs Forest NSW 2086 Australia
Other Offices	Europe Pharmaxis Pharmaceuticals Limited The Priory Stomp Road Burnham Buckinghamshire, SL1 7LW, UK Phone: 0044 (0) 1628 902110 Fax: 0044 (0) 1628 669355 Email: eu.info@pharmaxis.com United States Pharmaxis Inc 1 East Uwchlan Aveneue, Suite 405 Exton, PA 19341, US Phone: +1 610 363 5120 Fax: +1 610 363 5936 Email: usa.info@pharmaxis.com Asia Pharmaxis Shanghai Representative Office Suite 2223, 22F, Tomson Commercial Building 710 Dongfang Rd Pudong, Shanghai 200122 CHINA Phone: +86 21 6165 2223 Fax: +86 21 6165 2258 Email: phillip.gregory@pharmaxis.com.au
Sector	Life Science / Bio-Technology / Pharmaceutical
Internet Homepage Address (URL)	http://www.pharmaxis.com.au
Phone Number	61 2 9454 7200
Fax Number	61 2 9451 3622
Email Address	Info@pharmaxis.com.au
Financial Year End	June 30
Board of Directors	Malcolm McComas (Independent Chairman) (Appointed on 1 May 2012) Alan Robertson (CEO) Will Delaat Richard van den Broek Dr John Villiger Denis Hanley (Retired as Chairman and director on 1 May 2012)
Company Secretary and Chief Financial Officer	David McGarvey
Management Team	Alan D Robertson BSc PhD Chief Executive Officer David McGarvey BA CA Chief Financial Officer Brett Charlton MBBS PhD Medical Director Gary Phillips BPharm MBA Chief Operating Officer John Crapper BSc MBA Operations Director Ian McDonald BSc PhD Chief Scientific Officer Dr Howard Fox Chief Medical Officer
Investor Relations Contact	David McGarvey
Principal Bankers	HSBC Bank Australia Ltd Westpac Banking Corporation
Auditors	PricewaterhouseCoopers Darling Park Tower 2 201 Sussex Street Sydney NSW 2000 Australia
Legal Advisors	PFM Legal Pty Ltd Level 12 117 York Street Sydney NSW 2000 Australia Venable LLP 575 7th Street, NW Washington, DC 20004 United States of America
Share Registry	Computershare Investor Services Pty Ltd Level 3, 60 Carrington Street Sydney NSW 2000 Australia Telephone: 1300 855 080 Fax: 61 3 9473 2500 www.computershare.com
ADR Registrar and Transfer Agent	BNY Mellon Shareowner Services 480 Washington Blvd., 27th floor Jersey City, NJ 07310 Telephone within the U.S.: (201) 680-4000 Telephone outside the U.S.: +1 201 680 6825
Stock Symbol	ASX Stock Code: PXS OTC: PXSLY
Listing Date	ASX: November 2003 NASDAQ: Aug 2005 (Voluntarily de-listed on 03 Aug 2009)
Number of Shares	229m (as at 30 September 2011)
Number of Options	12m (as at 30 September 2011)
Share Capital	Institutions (62 institutions) : 59% Management : 5% Others / Retail : 36% (as at 30 September 2011)
Employees	129 (as at 30 September 2011)
Cash	$34m (as at 30 September 2011)
Corporate Objective	The development of products for respiratory diseases
Discovery	PXS25 (M6P receptor blocker); VAP1 inhibitor
Lead Products	Aridol: assessment of asthma and COPD approved & launched in major markets   Bronchitol for cystic fibrosis: approved in Australia recommended for approval in EU US NDA in preparation   Bronchitol for bronchiectasis: Phase III trial in progress   ASM8 for asthma: Phase II trial in progress
Key Patents	Aridol & Bronchitol granted in USA, EU, Australia, Asia, Canada; pending in Japan
ACN	082 811 630